Adial Pharmaceuticals Inc (ADIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has a cash flow conversion efficiency ratio of -0.434x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.61 Million) by net assets ($3.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Adial Pharmaceuticals Inc (ADIL) total market value for the company's overall valuation and market capitalisation.
Adial Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adial Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See Adial Pharmaceuticals Inc (ADIL) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NeuroMetrix Inc
NASDAQ:NURO
|
-0.132x |
|
HK Metals Utama Tbk PT
JK:HKMU
|
0.222x |
|
Pharmena S.A.
WAR:PHR
|
-0.078x |
|
Terrain Minerals Ltd
AU:TMX
|
-0.113x |
|
Nuchev Ltd
AU:NUC
|
-0.107x |
|
Cabnet Holdings Bhd
KLSE:0191
|
0.009x |
|
China Aoyuan Group Limited
F:47C
|
-0.051x |
|
Check Cap Ltd
NASDAQ:CHEK
|
0.000x |
Annual Cash Flow Conversion Efficiency for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Adial Pharmaceuticals Inc from 2015 to 2025. View current stock price of Adial Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.28 Million | $-6.49 Million | -1.230x | +27.69% |
| 2024-12-31 | $4.07 Million | $-6.92 Million | -1.702x | -2.08% |
| 2023-12-31 | $4.08 Million | $-6.81 Million | -1.667x | +51.17% |
| 2022-12-31 | $3.28 Million | $-11.19 Million | -3.414x | -0.22% |
| 2021-12-31 | $3.51 Million | $-11.95 Million | -3.407x | -77.89% |
| 2020-12-31 | $3.99 Million | $-7.63 Million | -1.915x | -115.72% |
| 2019-12-31 | $7.14 Million | $-6.34 Million | -0.888x | -57.80% |
| 2018-12-31 | $4.44 Million | $-2.50 Million | -0.563x | -213.40% |
| 2017-12-31 | $-997.55K | $-494.86K | 0.496x | -81.29% |
| 2016-12-31 | $-103.49K | $-274.38K | 2.651x | +192.97% |
| 2015-12-31 | $163.15K | $-465.22K | -2.852x | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more